Daily FNArena News - Small Caps

Brokers welcome Life360’s new advertising initiative unveiled at the same time as FY23 results and FY24 guidance which both exceeded expectations

Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to stringent cost control

Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked

Dicker data shares fell -10% yesterday but it had nothing to do with the company’s AI-fuelled outlook

Profit season brings out the best and worst in small caps, and sometimes both at once, reports The New Criterion’s Tim Boreham

A disappointing update on recently acquired powercloud does not ruin the investment case for Hansen Technologies, analysts say

While Data3#’s earnings result confirmed its January trading update, the market was not impressed with how profit growth was achieved

Run-of-the-mill accounting software company Reckon may be set for a re-rating, brokers believe

Artificial intelligence and some valuable experiences should benefit heart device developer Artrya, Tim Boreham explains

Some cannabis gems are sprouting in the ASX weed patch, but they are hard to find in the haze of hype, Tim Boreham, Editor, The New Criterion reports